---
title: "Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations"
description: "Formulary evidence on Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| A-aDO2 | Alveolar-arterial oxygen difference |
| AHFS | American Hospital Formulary Service |
| aPAP | Autoimmune pulmonary alveolar proteinosis |
| ATC | Anatomical Therapeutic Chemical classification |
| ATS | American Thoracic Society |
| BLA | Biologics License Application |
| CI | Confidence interval |
| COVID-19 | Coronavirus disease 2019 |
| CYFRA21-1 | Cytokeratin 19 fragment |
| DBSC | Dried blood spot card |
| DLCO | Diffusing capacity of the lungs for carbon monoxide |
| DLCOadj | Diffusing capacity of the lungs for carbon monoxide adjusted for hemoglobin |
| EC | Exercise capacity |
| EMA | European Medicines Agency |
| EQ-5D-5L | EuroQol 5 Dimensions, 5 Levels |
| ERS | European Respiratory Society |
| ETD | Estimated treatment difference |
| FAS | Full analysis set |
| FDA | U.S. Food and Drug Administration |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GMAb | GM-CSF autoantibody |
| HRQoL | Health-related quality of life |
| IMP | Investigational medicinal product |
| KL-6 | Krebs von den Lungen-6 |
| LDH | Lactate dehydrogenase |
| LSM | Least-squares mean |
| MAA | Marketing Authorisation Application |
| MAD | Multiple ascending dose |
| MD | Mean difference |
| MET | Metabolic equivalent |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MOL-MOL | Molgramostim during both double-blind and open-label treatment |
| NS | Not significant |
| PAP | Pulmonary alveolar proteinosis |
| PBO | Placebo |
| PD | Pharmacodynamics |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PRO | Patient-reported outcome |
| RTF | Refusal to File |
| SAD | Single ascending dose |
| SGRQ | St. George’s Respiratory Questionnaire |
| SGRQ-A | St. George’s Respiratory Questionnaire Activity score |
| WBC | White blood cell |
| WLL | Whole lung lavage |

## Related pages
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis.md)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic information and modeling report](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: prevalence by geography](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses.md)
